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Poster Session II S277have significant influence. Recipient with TNFB + 252 G allele-
positive was a less significant factor (RR5 1.823, P5 0.063). (3)
Relapse was observed more frequently among patients who had
not previously developed aGVHD (P5 0.03). Except TNFRII
196 T/T genotype in recipients side was related to lower relapse
rate(P5 0.05), no significant association was found between cyto-
kine genes polymorphisms with cGVHD, relapse and overall
survival.
Conclusions: These results, which is the first report of TNFA,
TNFB and TNFRII polymorphic features of Chinese population
with the outcomes of HSCT, suggest an interaction of TNFA-
857, TNFB + 252 genotypes on risk of aGVHD.320
RAPID SWITCH TO DONOR-TYPE DOMINANT CHIMERISM AND EARLY
LYMPHOCYTE RECOVERY FOLLOWING REDUCED-INTENSITY CORD
BLOOD TRANSPLANTATION
Uchida, N.1, Wake, A.1, Yamamoto, H.1, Yoneyama, A.2, Nishida, A.1,
Shimazu, H.1, Nakano, N.1, Ishiwata, K.1, Tsuji, M.1, Asano-
Mori, Y.1, Makino, S.3, Masuoka, K.4, Taniguchi, S.1 1 Toranomon Hos-
pital, Tokyo, Japan; 2 Toranomon Hospital, Tokyo, Japan; 3 Toranomon
Hospital, Tokyo, Japan; 4 Mishuku Hospital, Tokyo, Japan
Although immune cells in cord blood (CB) are immature, several
lines of evidence suggested that they are potentially active from
very early timing post-transplant, such as severe immune reaction
observed at around day 9 (Kishi, Transplantation 2005, Barker,
BMT Tandem meetings 2009), or the impact of HLA disparity
in GVH direction on engraftment failure (Matsuno, Blood 2009).
We conducted a retrospective study to investigate the kinetics of
donor-recipient chimerism and lymphocyte recovery (LR) during
early period after CBT. Data were collected from 109 patients
who underwent first CBT using fludarabine (Flu)-containing regi-
men since June 2007 to Feb. 2009 at Toranomon Hospital. Pa-
tients who had non-malignant diseases, died within 30 days, or
had disease progression before engraftment or within 30 days
post-transplant were excluded, and 47 were subjected to the analy-
sis. 21 out of 26 recipients of unrelated bone marrow (UBM) trans-
planted during the same period were selected as above and were
used as a control. Patients received Flu along with melphalan, bu-
sulfan, and total body irradiation in various combinations. Tacroli-
mus (Tac)+mycophenolate mofetil (n5 42) or Tac alone (n5 5)
were used for CB recipients and Tac+methotrexate was for all
UBM recipients as GVHD prophylaxis. 1 or 2-antigen mismatched
CB units were used at a median 2.56 (1.96-4.31) 107/kg of TNC
and 0.87 (0.4-6.32) 105/kg of CD34+ cells. 45 out of 47 CB recip-
ients achieved neutrophil recovery $500/ml at a median of 22 (13-
43) days, whereas all UBM recipients did at a median of 20 (16-41)
days (P5 0.17). In CB recipients, 30 patients were assessed donor-
recipient chimeric status in 16 days post-transplant, and, remark-
ably, 28 (93%) achieved complete (.90%) donor-type, while in
UBM recipients, 7 were assessed and only 2 (29%) did
(P\.0001). LR was assessed by defining the first day of 3 consecu-
tive blood test showed lymphocyte (Ly) $100/ml as the date of LR.
44 (94%) CB recipients achieved LR at a median of 15 (10-37)
days, while all UBM recipients did at a median of 20 (13-29)
days (P5 0.17). The cumulative incidences of LR achievement
up to day 19 were 646 0.5 in CB and 386 1.2 in UBM recipients
(P5.016). Flow cytometric analysis of Ly at around day 14 (13-17)
post-CBT, assessed in 30 patients, showed CD8+ T cell pedomi-
nance (506 5% of Ly). In conclusion, the results indicate
extremely powerful proliferative potential of CB Ly after transplan-
tation which may surpass that of UBM Ly.321
PREMALIGNANT AND MALIGNANT ORAL CHANGES FOLLOWING ALLO-
GENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Mawardi, H.1, Elad, S.2, Correa, M.3, Stevenson, K.4, Woo, S.-B.1,5,
Lerman, M.1,5, Antin, J.6, Soiffer, R.6, Treister, N.1,5 1 Harvard Schoolof Dental Medicine, Boston, MA; 2 Hebrew University–Hadassah School
of Dental Medicine, Jerusalem, Israel; 3 University of Campinas, Sao
Paulo, Brazil; 4 Dana-Farber Cancer Institute, Boston, MA; 5 Brigham
and Women’s Hospital, Boston, MA; 6 Dana-Farber Cancer Institute,
Boston, MA
a) Background: Allogeneic hematopoietic cell transplantation
(HSCT) is associated with a wide range of complications and late ef-
fects, including secondary solid tumors, of which oral carcinoma is
one of the most common. The purpose of this study was to describe
the clinical characteristics of a large series of patients treated with
HSCT that subsequently developed oral premalignant or malignant
lesions.
b) Methods: The records of patients who received HSCT and
developed oral pre/malignant lesions at 3 centers were reviewed. De-
scriptive statistics included HSCT course including chronic graft-
versus-host disease (cGVHD) and details of oral neoplasm including
presentation, diagnosis and management; survival calculations were
also performed.
c) Results: Twenty-four patients were identified that developed
premalignant (n5 8) or malignant (n5 16) oral mucosal disease
at a median time of 3 and 9 years, respectively. Of the 22 that
had developed cGVHD, 95% (21/22) presented with oral features.
Of those that developed carcinoma, 25% had multifocal involve-
ment. The tongue was the most common site (n5 7; 44%), fol-
lowed by lower lip and buccal mucosa (n5 2; 12% for both
sites). Dysplasia preceded diagnosis of carcinoma in 13% of cases.
Localized recurrence occurred in 29% of cases with 5-year freedom
from recurrence of 46% 6 16. Five-year overall survival was 75%
6 22 for patients with premalignant changes and 67% 6 16 for pa-
tients with carcinoma.
d) Conclusions: Patients undergoing HSCT are at risk of develop-
ing new solid cancers, specifically in the mouth. As the majority of
patients in this series were previously diagnosed with oral cGVHD,
and many cases were multifocal/recurrent, this supports the theory
of field cancerization and suggests that these cancers may be more
aggressive than in non-HSCT patients. In addition, this highlights
the importance of comprehensive oral examination and vigilant fol-
low-up. Further studies examining the biological and molecular
processes of tumor development in this high-risk population are
needed.322
GENOTYPING OF HUMAN CYTOMEGALOVIRUS (HCMV) IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
Dieamant, D.C.1, Bonon, S.H.A.1, Murakami, M.M.1, Costa, S.C.B.1,
Vigorito, A.C.2 1 State University of Campinas-UNICAMP, Campinas,
Sa˜o Paulo, Brazil; 2 State University of Campinas-UNICAMP, Campi-
nas, Sa˜o Paulo, Brazil
Based on sequence variation in theUL55 gene that encodes glyco-
protein B (gB), human cytomegalovirus (HCMV) can be classified
into four gB genotypes. Previous studies have suggested there could
be an association betweenCMVgB genotype and clinical outcome in
patients who underwent an allogeneic hematopoietic stem cell trans-
plant (HSCT).
Objectives: The goal of this study was to determine the distri-
bution of gB genotypes in allogeneic HSCT patients with CMV
infection and the effect of gB type on clinical outcome includ-
ing CMV disease. Study design: DNA was extracted directly
from the blood of 41 allogeneic HSCT recipients. Antigen
pp65-HCMV and HCMV-DNA was detected by AGM and
N-PCR, respectively. The gB genotype of CMV was determined
using the polymerase chain reaction to amplify a region of
UL55, followed by restriction analysis based on HinfI and
RsaI digestion.
Results:At a median time of 32 days after the transplant, 32/41
patients (78%) presented active HCMV infection detected by
AGM and/or N-PCR. So far, the distribution of HCMV gB ge-
notypes in 21/32 patients with HCMV active infection was as
follow: gB1, 9/21 (42,9%); gB2, 6/21 (28.6%); gB3, 2/21
(9,5%); gB4, 2/21 (9,5%) and two patients (9,5%) had mixed
S278 Poster Session IIinfection whit gB1+gB3 and gB2 + gB3. HCMV disease devel-
oped in 2 patients, characterized for gastrointestinal disease and
these two patients had infection with a mixture of HCMV gB
genotypes.
Conclusions: in this study the most prevalent genotype in patients
with HCMV active infection was gB genotype 1 and moreover, the
mixture of HCMV gB genotypes was associate with gastrointestinal
disease. However, this study is limited due to the small number of
patients, thus making it difficult to draw a firm conclusion regard-
ing the distribution of HCMV genotypes and their possible associ-
ation with outcome. Nevertheless, these results may be taken as
a preliminary report on the prevalence of different HCMV gB ge-
notypes in a Brazilian allogeneic HSCT population with active
HCMV infection.323
A PHASE I STUDY OF CLOFARABINE PLUS HIGH DOSE MELPHALAN AS A
CONDITIONING REGIMEN FOR ALLOGENEIC TRANSPLANTATION
Kirschbaum, M.H., Stein, A.S., Nakamura, R., Auayporn, N.,
Popplewell, L., Delioukina, M., Chen, R., Snyder, D., Conrad, J.,
Frankel, P., Forman, S.J. City of Hope National Cancer Center, Duarte,
CA
Background:Reduced intensity regimens for allo transplant suc-
cessfully replaced the alkylating agent cyclophosphamide with
the purine nucleoside antimetabolite, fludarabine, an immuno-
suppressive with a milder toxicity profile. Clofarabine is a purine
nucleoside analogue designed to exploit a double halogen strat-
egy which confers resistance to adenosine deaminase and makes
the drug more efficient than fludarabine at inhibiting ribonucle-
otide reductase and disrupting mitochondrial function, leading
to apoptosis.
Aims:To evaluate a clofarabine containing regimen as conditioning
for allogeneic stem cell transplant.
Methods: phase I dose escalation: clofarabine (dose level
one5 30 mg/m2, dose level two and three5 40 mg/m2) IV daily
days –7 to day –3 infused over 30 minutes IV, plus Melphalan
(dose level one and two, 100 mg/m2, dose level three, 140 mg/
m2) administered over 30 minutes IV on day –2. Related or un-
related allogeneic stem cells were infused on day 0. GVHD
prophylaxis: initially CSP plus mycophenelate, then tacrolimus
plus sirolimus was adopted as per COH standard of care. Pa-
tients age$ 18 years with AML, ALL, MDS in CR1, CR2 or
in relapse (up to 50% marrow blasts), not deemed eligible for
standard transplant regimens, or at high risk for relapse, are
eligible.
Results: We report on the first 2 dose levels. 10 eligible pa-
tients, all with AML, have been treated thus far, 4 Males, 6 Fe-
males, with a median age of 62 years (39 – 65). 5 patients were
in CR1, 2 patients were in CR2, and 3 patients were trans-
planted in relapse. Grade 3 non-hematologic toxicities included
fatigue, elevation of AST and LFT, diarrhea, and hyponatremia
and mucositis (in one patient). No dose limiting toxicities
(DLT) were seen in level one. One patient in dose level 2
died prior to engraftment due to hepatic, renal, and infectious
toxicities; that dose level has been expanded thus far to seven
patients and no further DLT have been seen (one accrued pa-
tient was ineligible due to mismatch). Three patients in relapse
received an unrelated donor graft, had complete engraftment
and achieved remission. Engraftment data is presented in the
table below. Mild acute skin graft versus host disease (GvHD)
was seen in two patients, with mild gut GvHD responsive to
steroids seen in one patient, and mild chronic GvHD in one
patient.
Conclusion: The combination of clofarabine and melphalan is an
adequate conditioning regimen leading to complete engraftment of
allogeneic stem cells.Dose Days* to Days* to Months
Level Patient ANC$ 0.5x109/L PLT$ 100 Follow-up** Status1 1 14 15 20 Remission
1 2 14 13 20 Remission
1 3 24 23 18 Remission
2 4*** 1 Expired
2 5 13 13 16 Remission
2 6 17 13 10 Remission
2 7 12 14 8 Remission
2 8 16 14 6 Remission
2 10 12 13 1 Remission
2 11 16 15 1 Remissionmedian 14 14 9* - From Transplant ** - Days from transplant to relapse/death or last
contact *** - Patient expired prior to engraftment.324
DYSGLYCEMIA FOLLOWING GLUCOCORTICOID THERAPY FOR ACUTE
GRAFT VS. HOST DISEASE ADVERSELY AFFECTS TRANSPLANTATION
OUTCOMES
Pidala, J.1, Kim, J.2, Alsina, M.1, Ayala, E.1, Field, T.1, Fernandez, H.1,
Kharfan-Dabaja, M.1, Ochoa, L.1, Perez, L.1, Perkins, J.1, Tomblyn, M.1,
Anasetti, C.1 1 Moffitt Cancer Center, Tampa, FL; 2 Moffitt Cancer Cen-
ter, Tampa, FL
Disordered glucose metabolism is a common complication of glu-
cocorticoid therapy for acute graft vs. host disease (aGVHD) after al-
logeneic hematopoietic cell transplantation (HCT). We aimed to
examine the independent impact of serum glucose parameters (max-
imum,minimum,mean, and standard deviation) on outcomes in a se-
ries of 173 recipients of HCTwho were treated with glucocorticoids
for aGVHD.Median onset of aGVHDwas 23 days (range 5 – 1112).
Patients were treated with primarily 1 mg/kg of glucocorticoids for
biopsy-confirmed aGVHD. The median duration of glucocorticoid
therapywas 271 days (range 15 – 1632).Glucose valueswere obtained
from glucocorticoid initiation date to death or last follow up, result-
ing in a total of 13,170 values. Themedian (range) values for each pa-
rameter were: maximum 292 mg/dL (128 – 694), minimum 75 mg/
dL (34 – 142), mean 146 mg/dL (86 – 327), and standard deviation
47 mg/dL (12 – 108). Baseline diabetes mellitus predicted signifi-
cantly greater maximum, mean, and standard deviation. With a me-
dian follow up of 18 months, median overall survival (OS) was 16
months (95% CI 11 – 34). On multivariable analysis, maximum glu-
cose significantly predicted OS and non-relapse mortality (NRM).
Increased variability also predicted OS and NRM. Those with mini-
mum glucose values of (0 – 60 mg/dL) had increased NRM. Values
for minimum glucose demonstrated a non-linear relationship with
OS: those with minimum glucose of (0 – 60 mg/dL) as well as those
(81 – 150 mg/dL) had significantly worsened OS compared to (61 –
80 mg/dL). Minimum glucose of (81 – 150 mg/dL) was associated
with significantly increased risk for relapse. These data demonstrate
the adverse effect of dysglycemia in patients treated with glucocorti-
coids for aGVHD, and argue for stringent glycemic control in this
setting. Further efforts to reduce the burden of aGVHD, and its as-
sociated treatment with glucocorticoids are paramount.325
ALLOGENEIC HEMATOPOIETIC STEM TRANSPLANTATION DOES NOT
ERASE THE IMPACT OF THE NEW PROGNOSIS CLASSIFICATION IN AML
AND THE NEGATIVE INFLUENCE OF EVI1 AND FLT3 ITD MUTATIONS
Michallet, M., Sobh, M., Hayette, S., Charlot, C., El Hamri, M.,
Tedone, N., Nicolini, F.E., Ducastelle, S., Baracco, F., Tigaud, I.,
Thomas, X. Edouard Herriot Hospital, Lyon, France
We studied 78 patients who underwent an allogeneic HSCT for
AML and for whom we had cytogenetics and molecular markers.
